iBio, Inc. (IBIO) - 10-Q Filing Summary
Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026 (Fiscal Q3 2026)
Business Overview: iBio is a preclinical-stage biotechnology company utilizing an AI Drug Discovery Platform to develop precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. The company has no approved products and generates minimal revenue, relying on equity financing to fund operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2026 |
Nine Months Ended Mar 31, 2026 |
Nine Months Ended Mar 31, 2025 |
|---|---|---|---|
| Revenue | $0 | $100 | $200 |
| Net Loss | $(7,730) | $(22,443) | $(13,214) |
| Operating Expenses | $(8,365) | $(23,861) | $(13,604) |
| Research & Development | $(3,254) | $(11,084) | $(5,088) |
| General & Administrative | $(5,111) | $(12,777) | $(8,516) |
| Cash & Cash Equivalents (Balance) | $47,631 (as of Mar 31, 2026) | ||
| Investments in Debt Securities | $27,166 (as of Mar 31, 2026) | ||
| Total Current Assets | $77,251 (as of Mar 31, 2026) | ||
| Total Liabilities | $8,297 (as of Mar 31, 2026) | ||
| Accumulated Deficit | $(354,667) (as of Mar 31, 2026) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended March 31, 2026, increased to $22.4 million from $13.2 million in the prior year period. This was driven by higher R&D spending and a significant non-cash impairment charge.
- Intangible Asset Impairment: The company recorded a $5.0 million impairment charge related to the IBIO-101 asset (acquired from RubrYc) due to a strategic shift away from immuno-oncology toward obesity and cardiometabolic targets. This charge was included in G&A expenses.
- Capital Raise: Significant liquidity was added through financing activities. The company raised approximately $50 million in an underwritten public offering (August 2025), $26 million in a private placement (January 2026), and approximately $13.8 million from warrant exercises during the nine-month period.
- Debt Reduction: The company paid off its term promissory note and equipment financing loan in full during the period, resulting in zero debt balances for these instruments as of March 31, 2026.
- Investment Portfolio: The company invested approximately $27.2 million in debt securities (treasury bills/notes) during the period, which were not present in the prior year-end balance sheet.
Guidance, Outlook, and Risks
- Clinical Milestones:
- IBIO-600 (Anti-Myostatin): Received Clinical Trial Notification (CTN) acknowledgement from Australia's TGA. Phase 1a clinical trials are anticipated to commence in the second quarter of calendar 2026.
- IBIO-610 (Anti-Activin E): Development accelerated; first human clinical trials anticipated in the first half of calendar 2027.
- Liquidity Outlook: Management believes current cash, cash equivalents, and investments (approx. $74.8 million) are sufficient to fund operations for at least 12 months from the filing date. However, the company has a history of losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional financing.
- Strategic Shift: The company is actively seeking partners for its immuno-oncology assets (e.g., IBIO-101) to focus resources on its core obesity and cardiometabolic pipeline.
- Risks:
- Going Concern: Dependence on future equity financings to sustain operations.
- Regulatory Delays: Potential impact of U.S. federal government shutdowns on FDA review timelines and capital market access.
- Dilution: Significant dilution expected from the exercise of outstanding pre-funded warrants (approx. 89 million shares) and future equity offerings.
Investor Verification Checklist
- Warrant Expiration: Verify the impact of the April 8, 2026, public announcement triggering the expiration of Series G Warrants on May 20, 2026, and the subsequent exercise activity reported in subsequent events.
- IBIO-600 Trial Initiation: Confirm the actual start date of the Phase 1a clinical trial in Australia (anticipated Q2 2026) and any regulatory hurdles.
- Capital Runway: Monitor cash burn rate against the $74.8 million liquidity position to validate the 12-month runway assertion.
- Partnership Progress: Track progress on out-licensing or partnering for the immuno-oncology assets (IBIO-101) to offset the impairment loss.
- Government Shutdown Impact: Assess any delays in SEC registration statements or FDA interactions due to the partial U.S. federal government shutdown mentioned in the filing.